REGAIN: a randomized controlled clinical trial of oxaloacetate for improving the symptoms of long COVID
BackgroundLong COVID is characterized by fatigue, cognitive dysfunction, and other persistent symptoms. This randomized, double-blind, controlled trial evaluated the efficacy of oral oxaloacetate (OAA) in improving fatigue and cognitive function in adults with long COVID.MethodsA total of 69 partici...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnins.2025.1627462/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849430348289540096 |
|---|---|
| author | Suzanne D. Vernon Candace Rond Jennifer Bell Brindisi Butler Sara Isolampi Annaleah Otteson Pearl Phalwane Samantha Mower Shad Roundy David L. Kaufman Alan B. Cash Lucinda Bateman |
| author_facet | Suzanne D. Vernon Candace Rond Jennifer Bell Brindisi Butler Sara Isolampi Annaleah Otteson Pearl Phalwane Samantha Mower Shad Roundy David L. Kaufman Alan B. Cash Lucinda Bateman |
| author_sort | Suzanne D. Vernon |
| collection | DOAJ |
| description | BackgroundLong COVID is characterized by fatigue, cognitive dysfunction, and other persistent symptoms. This randomized, double-blind, controlled trial evaluated the efficacy of oral oxaloacetate (OAA) in improving fatigue and cognitive function in adults with long COVID.MethodsA total of 69 participants were randomized to receive either 2,000 mg/day of OAA or the control for 42 days. The primary outcome was fatigue reduction, measured by the Chalder Fatigue Questionnaire (CFQ). The secondary and exploratory outcomes included the DePaul Symptom Questionnaire Short Form (DSQ-SF), health-related quality of life (RAND-36), cognitive function (Defense Automated Neurobehavioral Assessment (DANA) Brain Vital), and time upright (UP Time).ResultsNo significant difference in the CFQ-measured fatigue reduction was observed between the groups. However, the OAA group showed significantly greater improvements in the DSQ-SF-measured fatigue and total symptom burden at day 21 of the trial. Cognitive performance improved significantly in the OAA group, with strong correlations between symptom response and cognitive gains. OAA was well tolerated.ConclusionOAA may contribute to earlier improvements in symptom burden and cognitive function in individuals with long COVID. Further studies are warranted. |
| format | Article |
| id | doaj-art-8a6317a514b248ec9d14018ff809a785 |
| institution | Kabale University |
| issn | 1662-453X |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neuroscience |
| spelling | doaj-art-8a6317a514b248ec9d14018ff809a7852025-08-20T03:28:01ZengFrontiers Media S.A.Frontiers in Neuroscience1662-453X2025-07-011910.3389/fnins.2025.16274621627462REGAIN: a randomized controlled clinical trial of oxaloacetate for improving the symptoms of long COVIDSuzanne D. Vernon0Candace Rond1Jennifer Bell2Brindisi Butler3Sara Isolampi4Annaleah Otteson5Pearl Phalwane6Samantha Mower7Shad Roundy8David L. Kaufman9Alan B. Cash10Lucinda Bateman11Bateman Horne Center, Salt Lake City, UT, United StatesBateman Horne Center, Salt Lake City, UT, United StatesBateman Horne Center, Salt Lake City, UT, United StatesBateman Horne Center, Salt Lake City, UT, United StatesBateman Horne Center, Salt Lake City, UT, United StatesBateman Horne Center, Salt Lake City, UT, United StatesBateman Horne Center, Salt Lake City, UT, United StatesDepartment of Mechanical Engineering, University of Utah, Salt Lake City, UT, United StatesDepartment of Mechanical Engineering, University of Utah, Salt Lake City, UT, United StatesCenter for Complex Diseases, Seattle, WA, United StatesTerra Biological LLC, San Diego, CA, United StatesBateman Horne Center, Salt Lake City, UT, United StatesBackgroundLong COVID is characterized by fatigue, cognitive dysfunction, and other persistent symptoms. This randomized, double-blind, controlled trial evaluated the efficacy of oral oxaloacetate (OAA) in improving fatigue and cognitive function in adults with long COVID.MethodsA total of 69 participants were randomized to receive either 2,000 mg/day of OAA or the control for 42 days. The primary outcome was fatigue reduction, measured by the Chalder Fatigue Questionnaire (CFQ). The secondary and exploratory outcomes included the DePaul Symptom Questionnaire Short Form (DSQ-SF), health-related quality of life (RAND-36), cognitive function (Defense Automated Neurobehavioral Assessment (DANA) Brain Vital), and time upright (UP Time).ResultsNo significant difference in the CFQ-measured fatigue reduction was observed between the groups. However, the OAA group showed significantly greater improvements in the DSQ-SF-measured fatigue and total symptom burden at day 21 of the trial. Cognitive performance improved significantly in the OAA group, with strong correlations between symptom response and cognitive gains. OAA was well tolerated.ConclusionOAA may contribute to earlier improvements in symptom burden and cognitive function in individuals with long COVID. Further studies are warranted.https://www.frontiersin.org/articles/10.3389/fnins.2025.1627462/fulloxaloacetatelong COVIDfatiguecognitive impaimentrandomized clinical trial |
| spellingShingle | Suzanne D. Vernon Candace Rond Jennifer Bell Brindisi Butler Sara Isolampi Annaleah Otteson Pearl Phalwane Samantha Mower Shad Roundy David L. Kaufman Alan B. Cash Lucinda Bateman REGAIN: a randomized controlled clinical trial of oxaloacetate for improving the symptoms of long COVID Frontiers in Neuroscience oxaloacetate long COVID fatigue cognitive impaiment randomized clinical trial |
| title | REGAIN: a randomized controlled clinical trial of oxaloacetate for improving the symptoms of long COVID |
| title_full | REGAIN: a randomized controlled clinical trial of oxaloacetate for improving the symptoms of long COVID |
| title_fullStr | REGAIN: a randomized controlled clinical trial of oxaloacetate for improving the symptoms of long COVID |
| title_full_unstemmed | REGAIN: a randomized controlled clinical trial of oxaloacetate for improving the symptoms of long COVID |
| title_short | REGAIN: a randomized controlled clinical trial of oxaloacetate for improving the symptoms of long COVID |
| title_sort | regain a randomized controlled clinical trial of oxaloacetate for improving the symptoms of long covid |
| topic | oxaloacetate long COVID fatigue cognitive impaiment randomized clinical trial |
| url | https://www.frontiersin.org/articles/10.3389/fnins.2025.1627462/full |
| work_keys_str_mv | AT suzannedvernon regainarandomizedcontrolledclinicaltrialofoxaloacetateforimprovingthesymptomsoflongcovid AT candacerond regainarandomizedcontrolledclinicaltrialofoxaloacetateforimprovingthesymptomsoflongcovid AT jenniferbell regainarandomizedcontrolledclinicaltrialofoxaloacetateforimprovingthesymptomsoflongcovid AT brindisibutler regainarandomizedcontrolledclinicaltrialofoxaloacetateforimprovingthesymptomsoflongcovid AT saraisolampi regainarandomizedcontrolledclinicaltrialofoxaloacetateforimprovingthesymptomsoflongcovid AT annaleahotteson regainarandomizedcontrolledclinicaltrialofoxaloacetateforimprovingthesymptomsoflongcovid AT pearlphalwane regainarandomizedcontrolledclinicaltrialofoxaloacetateforimprovingthesymptomsoflongcovid AT samanthamower regainarandomizedcontrolledclinicaltrialofoxaloacetateforimprovingthesymptomsoflongcovid AT shadroundy regainarandomizedcontrolledclinicaltrialofoxaloacetateforimprovingthesymptomsoflongcovid AT davidlkaufman regainarandomizedcontrolledclinicaltrialofoxaloacetateforimprovingthesymptomsoflongcovid AT alanbcash regainarandomizedcontrolledclinicaltrialofoxaloacetateforimprovingthesymptomsoflongcovid AT lucindabateman regainarandomizedcontrolledclinicaltrialofoxaloacetateforimprovingthesymptomsoflongcovid |